Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study-Reference-Cited by-同舟云学术

Cost-utility analysis of pharmacogenomics-guided tacrolimus treatment in Austrian kidney transplant recipients participating in the U-PGx PREPARE study

Published:2024-03-18 Issue:2 Volume:24 Page:
ISSN:1470-269X
Container-title:The Pharmacogenomics Journal
language:en
Short-container-title:Pharmacogenomics J

Author:

Fragoulakis Vasileios,Koufaki Margarita-Ioanna,Joefield-Roka Candace,Sunder-Plassmann Gere^ORCID,Mitropoulou Christina^ORCID

Funder

European Commission

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41397-024-00330-5.pdf

Reference26 articles.

1. Jones-Hughes T, Snowsill T, Haasova M, Coelho H, Crathorne L, Cooper C, et al. Immunosuppressive therapy for kidney transplantation in adults: a systematic review and economic model. NIHR J Libr. 2016;20:1–594.

2. Mudiayi D, Shojai S, Okpechi I, Christie EA, Wen K, Kamaleldin M, et al. Global estimates of capacity for kidney transplantation in world countries and regions. Transplantation. 2022;106:1113–22.

3. Chemello C, Aguilera M, Cañadas Garre M, Calleja MA. Pharmacogenetics and pharmacogenomics of chronic kidney disease comorbidities and kidney transplantation. In: Barh D et al., editors. Omics for personalized medicine. 1st ed. India: Springer eBooks; 2013. p.801–18.

4. Boenink R, Kramer A, Tuinhout RE, Savoye E, Åsberg A, Idrizi A, et al. Trends in kidney transplantation rate across Europe: study from the ERA Registry. Nephrol Dial Transpl. 2023;38:1528–39.

5. McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK. Pharmacoeconomics. 2006;24:67–79.